Sana Biotechnology Reports on Shareholder Vote Matters

Ticker: SANA · Form: 8-K · Filed: 2024-06-07T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Sana Biotech held a shareholder vote on June 6th, details to follow.

AI Summary

Sana Biotechnology, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders as of June 6, 2024. The filing does not contain specific details about the vote itself, such as proposals or outcomes, but confirms the event occurred.

Why It Matters

This filing indicates that Sana Biotechnology held a vote of its security holders, a standard corporate governance event that can signal important decisions or approvals are being made by the company.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure about a shareholder vote without immediate financial or operational implications.

Key Players & Entities

FAQ

What specific matters were submitted for a vote by Sana Biotechnology's security holders?

The filing does not specify the exact proposals or matters that were submitted for a vote by security holders on June 6, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on June 6, 2024.

What is the exact name of the registrant?

The exact name of the registrant is Sana Biotechnology, Inc.

In which state was Sana Biotechnology, Inc. incorporated?

Sana Biotechnology, Inc. was incorporated in Delaware.

What is the principal executive office address for Sana Biotechnology, Inc.?

The address of the principal executive offices is 188 East Blaine Street, Suite 400, Seattle, Washington 98102.

Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-06-07 16:05:15

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Sana Biotechnology, Inc. (the " Company ") held its 2024 annual meeting of stockholders (the " Annual Meeting ") on June 6, 2024. The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024. Proposal 1: The Company's stockholders elected all the nominees to serve as Class III directors of the Company's Board of Directors, each to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Joshua H. Bilenker, M.D. 148,997,261 16,148,638 13,427,015 Richard Mulligan, Ph.D. 149,561,266 14,901,700 14,109,948 Mary Agnes (Maggie) Wilderotter 144,161,860 20,256,138 14,154,916 Proposal 2: The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the votes set forth in the table below: For Against Abstain 178,501,678 65,444 5,792 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Sana Biotechnology, Inc. Date: June 7, 2024 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel 2

View on Read The Filing